This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
Human Genomics Open Access 25 April 2023
-
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Clinical Epigenetics Open Access 14 January 2021
-
MBASED: allele-specific expression detection in cancer tissues and cell lines
Genome Biology Open Access 07 August 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343–1345.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144–147.
Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839–843.
Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15: 5002–5007.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. International Vidaza High-Risk MDS Survival Study Group.v Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Fabiani E, Leone G, Giachelia M, D’alo F, Greco M, Criscuolo M et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010; 51: 2275–2284.
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Pic F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285–3291.
Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMMLpatients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923–3932.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147–1152.
Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009; 106: 16811–16816.
Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA . Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113: 4281–4288.
Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ et al. Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology 2010; 57: 814–824.
Acknowledgements
This work was supported by grants from Associazione Italiana Ricerca sul Cancro (GL and CM). We would like to acknowledge all Gimema centers who took part to the MDS0205 clinical trial.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MTV, PM, CF, VS and GL received ‘Honoraria’ from Celgene as speakers. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Voso, M., Fabiani, E., Piciocchi, A. et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia 25, 1910–1913 (2011). https://doi.org/10.1038/leu.2011.170
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.170
This article is cited by
-
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
Human Genomics (2023)
-
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Clinical Epigenetics (2021)
-
Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
Annals of Hematology (2018)
-
MBASED: allele-specific expression detection in cancer tissues and cell lines
Genome Biology (2014)
-
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
Leukemia (2014)